JAK inhibitor helps in refractory RA

A trial of the JAK inhibitor baricitinib shows it can reduce RA symptoms even in patients who have had a poor response to previous treatment, according to a report in the NEJM.

The three-armed randomised controlled trial divided 527 patients equally between 4mg and 2mg daily doses of the drug and placebo. Patients were enrolled at 178 centres across 24 countries.

Fifty-five percent of patients in